The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
ACG Case Rep J. 2021 May 14;8(5):e00581.doi: 10.14309/crj.0000000000000581. eCollection 2021 May.
Jason J John1, Richard K Sterling2
Author information
1Virginia Commonwealth University School of Medicine, Richmond, VA.
2Virginia Commonwealth University Medical Center, Department of Gastroenterology, Richmond, VA.
Abstract
Porphyria cutanea tarda (PCT) is the most common porphyria and has a strong association with hepatitis C virus (HCV) infection and iron overload. Previous HCV treatment regimens, including interferon with or without ribavirin, may precipitate PCT relapse. Few case reports have shown that newer oral therapies, such as direct-acting antiviral agents, can successfully treat PCT parallel with HCV treatment. We present a case of a patient with non-iron-associated mixed porphyria that dramatically improved with direct-acting antiviral agent therapy for his HCV supporting the association of porphyria with chronic HCV.